Immune complexes as therapy for autoimmunity

Journal of Clinical Investigation

Volumn 115, Issue 1, 2005, Pages 25-27

  Clynes, Raphael ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; RHESUS D ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BULLOUS SKIN DISEASE; GUILLAIN BARRE SYNDROME; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NOTE; PATHOLOGY;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RHO(D) IMMUNE GLOBULIN;

EID: 85047691387     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23994     Document Type: Review

References (29)

1. Alves-Rosa, F., et al. 2000. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood. 96:2834-2840.
2. Clynes, R., and Ravetch, J.V. 1995. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 3:21-26.
3. Sylvestre, D., et al. 1996. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 184:2385-2392.
4. Samuelsson, A., Towers, T.L., and Ravetch, J.V. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 291:484-486.
5. Clarkson, S.B., et al. 1986. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N. Engl. J. Med. 314:1236-1239.
6. Crow, A.R., et al. 2003. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood. 102:558-560.
7. van Mirre, E., van Royen, A., and Hack, C.E. 2004. IVIg-mediated amelioration of murine ITP via FcgammaRIIb is not necessarily independent of SHIP-1 and SHP-1 activity. Blood. 103:1973-1974.
8. Bruhns, P., et al. 2003. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 18:573-581.
9. Akilesh, S., et al. 2004. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113:1328-1333. doi:10.1172/JCI200418838.
10. Hansen, R.J., and Balthasar, J.P. 2002. Intravenous immunoglobulin mediates an increase in antiplatelet antibody clearance via the FcRn receptor. Thromb. Haemost. 88:898-899.
11. Siragam, V., et al. 2005. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J. Clin. Invest. 115:155-160. doi:10.1172/JCI200522753.
12. Song, S., et al. 2003. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood. 101:3708-3713.
13. Scaradavou, A., and Bussel, J.B. 1998. Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura. Semin. Hematol. 35(Suppl. 1):52-57.
14. Sutterwala, F.S., et al. 1997. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J. Exp. Med. 185:1977-1985.
15. Sutterwala, F.S., et al. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J. Exp. Med. 188:217-222.
16. Cooper, N., et al. 2004. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br. J. Haematol. 124:511-518.
17. Coopamah, M.D., Freedman, J., and Semple, J.W. 2003. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood. 102:2862-2867.
18. Bazin, R., Lemieux, R., Tremblay, T., and St. Amour, I. 2004. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br. J. Haematol. 127:90-96.
19. Maeda, H., et al. 2001. Successful treatment of "malignant rheumatoid arthritis" in Japan with pooled intravenous immunoglobulin. Rheumatology. 40:955-956.
20. Diaz de Stahl, T., et al. 2002. Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur. J. Immunol. 32:2915-2922.
21. Ioan-Facsinay, A., et al. 2002. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity. 16:391-402.
22. Ji, H., et al. 2002. Arthritis critically dependent on innate immune system players. Immunity. 16:157-168.
23. Kaplan, C.D., et al. 2002. Development of inflammation in proteoglycan-induced arthritis is dependent on Fc gamma R regulation of the cytokine/chemokine environment. J. Immunol. 169:5851-5859.
24. Kleinau, S., Martinsson, P., and Heyman, B. 2000. Induction and suppression of collagen-induced arthritis is dependent on distinct fcgamma receptors. J. Exp. Med. 191:1611-1616.
25. Looney, R.J., Anolik, J., and Sanz, I. 2004. B cells as therapeutic targets for rheumatic diseases. Curr. Opin. Rheumatol. 16:180-185.
26. Abdul-Majid, K.B., et al. 2002. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 55:70-81.
27. Lock, C., et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-508.
28. Pedotti, R., et al. 2003. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc. Natl. Acad. Sci. U. S. A. 100:1867-1872.
29. Robbie-Ryan, M., et al. 2003. Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity. J. Immunol. 170:1630-1634.